EP3862348A4 - ISOINDOLINE COMPOUND, METHOD FOR PREPARATION, PHARMACEUTICAL COMPOSITION AND USE THEREOF - Google Patents

ISOINDOLINE COMPOUND, METHOD FOR PREPARATION, PHARMACEUTICAL COMPOSITION AND USE THEREOF Download PDF

Info

Publication number
EP3862348A4
EP3862348A4 EP19867602.5A EP19867602A EP3862348A4 EP 3862348 A4 EP3862348 A4 EP 3862348A4 EP 19867602 A EP19867602 A EP 19867602A EP 3862348 A4 EP3862348 A4 EP 3862348A4
Authority
EP
European Patent Office
Prior art keywords
preparation
pharmaceutical composition
isoindoline compound
isoindoline
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP19867602.5A
Other languages
German (de)
French (fr)
Other versions
EP3862348A1 (en
Inventor
Xiaohua Chen
Jia Li
Yu Cheng
Yubo ZHOU
Huijun NIE
Yujie Wang
Hongtao Tian
Weijuan KAN
Tian MI
Xiaobei HU
Binshan ZHOU
Kenian YAN
Gaoya XU
Yuhua ZHONG
Lei Feng
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Institute of Materia Medica of CAS
Original Assignee
Shanghai Institute of Materia Medica of CAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Institute of Materia Medica of CAS filed Critical Shanghai Institute of Materia Medica of CAS
Publication of EP3862348A1 publication Critical patent/EP3862348A1/en
Publication of EP3862348A4 publication Critical patent/EP3862348A4/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
    • C07D419/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP19867602.5A 2018-09-30 2019-09-30 ISOINDOLINE COMPOUND, METHOD FOR PREPARATION, PHARMACEUTICAL COMPOSITION AND USE THEREOF Pending EP3862348A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201811156797 2018-09-30
PCT/CN2019/109368 WO2020064002A1 (en) 2018-09-30 2019-09-30 Isoindoline compound, preparation method, pharmaceutical composition and use thereof

Publications (2)

Publication Number Publication Date
EP3862348A1 EP3862348A1 (en) 2021-08-11
EP3862348A4 true EP3862348A4 (en) 2022-06-22

Family

ID=69949418

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19867602.5A Pending EP3862348A4 (en) 2018-09-30 2019-09-30 ISOINDOLINE COMPOUND, METHOD FOR PREPARATION, PHARMACEUTICAL COMPOSITION AND USE THEREOF

Country Status (9)

Country Link
US (1) US12459921B2 (en)
EP (1) EP3862348A4 (en)
JP (1) JP7168773B2 (en)
KR (1) KR102672549B1 (en)
CN (2) CN110963994B (en)
AU (1) AU2019348094B2 (en)
BR (1) BR112021006458A2 (en)
CA (1) CA3121667A1 (en)
WO (1) WO2020064002A1 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3932922A4 (en) 2019-02-25 2022-05-11 ShanghaiTech University GLUTARIMIDE SKELETON SULFUR-CONTAINING COMPOUND AND USE THEREOF
WO2021023233A1 (en) 2019-08-05 2021-02-11 上海科技大学 Egfr protein degradant and anti-tumor application thereof
WO2021083328A1 (en) * 2019-10-30 2021-05-06 中国科学院上海药物研究所 Polysubstituted isoindoline compounds, preparation method therefor, pharmaceutical composition thereof and use thereof
CA3169011A1 (en) * 2020-02-25 2021-09-02 Xiaobao Yang Glutarimide skeleton-based compounds and uses thereof
EP4183781A4 (en) 2020-07-20 2024-01-03 Jiangsu Hengrui Pharmaceuticals Co., Ltd. SULFUR CONTAINING ISOINDOLINE DERIVATIVE AND PRODUCTION METHOD THEREOF AND MEDICAL USE THEREOF
CN114456173B (en) * 2020-11-10 2023-09-19 江苏恒瑞医药股份有限公司 Condensed ring group substituted cyclohexanediimide derivative, preparation method and medical application thereof
WO2022148358A1 (en) * 2021-01-05 2022-07-14 江苏恒瑞医药股份有限公司 Cyclohexadiimide derivative substituted by fused heterocyclyl, and preparation method therefor and pharmaceutical application thereof
CN116368131B (en) * 2021-01-11 2024-09-20 和径医药科技（上海）有限公司 A new type of Smad3 protein degrader and its application
JP2024504932A (en) 2021-01-13 2024-02-02 モンテ ローザ セラピューティクス， インコーポレイテッド isoindolinone compound
GB202114315D0 (en) * 2021-10-06 2021-11-17 Duke Street Bio Ltd Pharmaceutical compound
US20240217968A1 (en) * 2021-03-31 2024-07-04 Duke Street Bio Limited Pharmaceutical compound
CN115504963A (en) * 2021-06-22 2022-12-23 苏州开拓药业股份有限公司 A c-Myc protein degradation agent
WO2023138647A1 (en) 2022-01-19 2023-07-27 江苏恒瑞医药股份有限公司 Crystalline form of sulfur-containing isoindoline derivative
EP4490160A4 (en) * 2022-03-11 2026-03-11 Univ Cornell SMALL MOLECULAR INTHIBITORS OF CRL4-UBIQUITIN LIGASES
CN117088864B (en) * 2022-05-13 2026-03-03 广州智药生物科技有限公司 Benzo [ d ] isoxazole compound and application thereof
CN118019736A (en) * 2022-09-08 2024-05-10 标新生物医药科技(上海)有限公司 Molecular glue compounds designed based on cereblon protein and their applications
CN118556047A (en) * 2022-12-27 2024-08-27 标新生物医药科技(上海)有限公司 Oxo-isoindolinyl substituted piperidinedione derivative and application thereof
WO2024192146A2 (en) * 2023-03-14 2024-09-19 Southern Research Institute Compounds for the treatment of cystic fibrosis
WO2024222918A1 (en) * 2023-04-28 2024-10-31 中国药科大学 Benzo six-membered heterocyclic gspt1 protein degradation agent and use thereof
CN119451952A (en) * 2023-06-01 2025-02-14 标新生物医药科技(上海)有限公司 Oxoisoindolyl-substituted tetrahydropyrimidinedione derivatives and their applications
WO2025016359A1 (en) * 2023-07-14 2025-01-23 标新生物医药科技(上海)有限公司 Glutarimide isoindolinone skeleton-based compound
CN119613374A (en) * 2023-09-14 2025-03-14 中国科学院上海药物研究所 Indazolone compounds, preparation methods, pharmaceutical compositions and applications thereof
CN117164597B (en) * 2023-11-02 2024-02-09 深圳创元生物医药科技有限公司 SMTP-0 synthesis method

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007027527A2 (en) * 2005-08-31 2007-03-08 Celgene Corporation Isoindole-imide compounds and compositions comprising and methods of using the same
WO2008115516A2 (en) * 2007-03-20 2008-09-25 Celgene Corporation 4'-o-substituted isoindoline derivatives and compositions comprising and methods of using the same
WO2017212329A1 (en) * 2016-06-10 2017-12-14 Otsuka Pharmaceutical Co., Ltd. Cliptac composition
WO2020106933A1 (en) * 2018-11-21 2020-05-28 Accutar Biotechnology Inc. Novel compounds having estrogen receptor alpha degradation activity and uses thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8877780B2 (en) 2006-08-30 2014-11-04 Celgene Corporation 5-substituted isoindoline compounds
MX2009001989A (en) 2006-08-30 2009-03-09 Celgene Corp 5-substituted isoindoline compounds.
US9045453B2 (en) 2008-11-14 2015-06-02 Concert Pharmaceuticals, Inc. Substituted dioxopiperidinyl phthalimide derivatives
EP2536706B1 (en) 2010-02-11 2017-06-14 Celgene Corporation Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
CN111205268B (en) * 2014-10-30 2021-01-26 康朴生物医药技术（上海）有限公司 Isoindoline derivative, intermediate thereof, preparation method, pharmaceutical composition and application
JP6815318B2 (en) * 2014-12-23 2021-01-20 ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド How to Induce Targeted Proteolysis by Bifunctional Molecules
WO2017176958A1 (en) * 2016-04-06 2017-10-12 The Regents Of The University Of Michigan Monofunctional intermediates for ligand-dependent target protein degradation
MX384905B (en) * 2016-04-12 2025-03-14 Univ Michigan Regents BROMODOLA AND EXTRATERMINAL DOMAIN (BET) PROTEIN DEGRADERS.
CN109790143A (en) 2016-05-10 2019-05-21 C4医药公司 The C of amine connection for target protein degradation3Glutarimide degron body
AU2017263574B2 (en) * 2016-05-12 2022-11-17 The Regents Of The University Of Michigan ASH1L inhibitors and methods of treatment therewith
AU2017281903B2 (en) * 2016-06-23 2020-12-24 Dana-Farber Cancer Institute, Inc. Degradation of bromodomain-containing protein 9 (BRD9) by conjugation of BRD9 inhibitors with E3 ligase ligand and methods of use
CN117510491A (en) * 2016-12-23 2024-02-06 阿尔维纳斯运营股份有限公司 Compounds and methods for targeted degradation of rapidly accelerating fibrosarcoma polypeptides
IL315310A (en) * 2017-12-26 2024-10-01 Kymera Therapeutics Inc IRAK joints and used in them
JP2021519337A (en) 2018-03-26 2021-08-10 シー４ セラピューティクス， インコーポレイテッド Cereblon binder for the degradation of Ikaras
WO2019213005A1 (en) * 2018-04-30 2019-11-07 Dana-Farber Cancer Institute, Inc. Small molecule degraders of polybromo-1 (pbrm1)
EP3896062A4 (en) * 2018-12-06 2022-06-15 Shanghai Institute of Materia Medica, Chinese Academy of Sciences Isoindoline compound, and preparation method, pharmaceutical composition, and application of isoindoline compound

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007027527A2 (en) * 2005-08-31 2007-03-08 Celgene Corporation Isoindole-imide compounds and compositions comprising and methods of using the same
WO2008115516A2 (en) * 2007-03-20 2008-09-25 Celgene Corporation 4'-o-substituted isoindoline derivatives and compositions comprising and methods of using the same
WO2017212329A1 (en) * 2016-06-10 2017-12-14 Otsuka Pharmaceutical Co., Ltd. Cliptac composition
WO2020106933A1 (en) * 2018-11-21 2020-05-28 Accutar Biotechnology Inc. Novel compounds having estrogen receptor alpha degradation activity and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2020064002A1 *

Also Published As

Publication number Publication date
CN114085212B (en) 2023-05-02
CN110963994B (en) 2022-02-08
KR102672549B1 (en) 2024-06-10
KR20210069085A (en) 2021-06-10
BR112021006458A2 (en) 2021-07-06
WO2020064002A1 (en) 2020-04-02
JP2022503942A (en) 2022-01-12
CN114085212A (en) 2022-02-25
NZ775500A (en) 2024-04-26
JP7168773B2 (en) 2022-11-09
EP3862348A1 (en) 2021-08-11
CN110963994A (en) 2020-04-07
US12459921B2 (en) 2025-11-04
AU2019348094B2 (en) 2022-12-22
CA3121667A1 (en) 2020-04-02
AU2019348094A1 (en) 2021-05-27
US20220041576A1 (en) 2022-02-10

Similar Documents

Publication Publication Date Title
EP3862348A4 (en) ISOINDOLINE COMPOUND, METHOD FOR PREPARATION, PHARMACEUTICAL COMPOSITION AND USE THEREOF
EP4053118A4 (en) SUBSTITUTED HETEROCYCLIC CONDENSED CYCLIC COMPOUND, METHOD FOR PREPARATION AND PHARMACEUTICAL USE
EP3964516A4 (en) OXAAZAQUINAZOLINE-7(8H)-KETONE COMPOUND, METHOD FOR PREPARATION AND PHARMACEUTICAL APPLICATION
EP3483142A4 (en) AROMATIC ACETYLENE OR AROMATIC ETHYLENE COMPOUND, INTERMEDIATE PRODUCT, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF
EP3486242A4 (en) OXOPICOLINAMIDE DERIVATIVE, PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICAL USE THEREOF
EP3903830A4 (en) NUCLEIC ACID, COMPOSITION AND CONJUGATE CONTAINING A NUCLEIC ACID, METHOD FOR THE PREPARATION AND USE THEREOF
EP3351242A4 (en) ORAL PHARMACEUTICAL COMPOSITION COMPRISING CANNABINOID, PROCESS FOR PREPARATION AND USE THEREOF
EP3536698A4 (en) LANOSTEROL-BASED DRUG COMPOUND, PREPARATION METHOD AND USE THEREOF
EP3502105A4 (en) POLYMORPHIC FORM OF A KINASE INHIBITOR COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING THE SAME, PREPARATION METHOD AND USE THEREOF
EP3929198A4 (en) HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING IT, METHOD FOR PREPARING IT AND ITS USE
EP4053151A4 (en) KERATIN BD-1, PREPARATION METHOD, AS WELL AS PHARMACEUTICAL COMPOSITION AND USE THEREOF
EP4056571A4 (en) TRICYCLIC DIHYDROIMIDAZOPYRIMIDONE DERIVATIVE, ITS PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND ITS USE
EP4079734A4 (en) TRIAZOLOPYRIDAZINE DERIVATIVE, METHOD FOR PREPARING IT, PHARMACEUTICAL COMPOSITION THEREOF AND CORRESPONDING USE
EP3012256A4 (en) HETEROCYCLIC BENZIMIDAZOLE-2-PIPERAZINE COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING THE SAME, PROCESS FOR PREPARATION AND USE THEREOF
EP3750886A4 (en) TETRAHYDROISOQUINOLEIN COMPOUND, PROCESS FOR PREPARATION, PHARMACEUTICAL COMPOSITION IN CONTAINER AND ASSOCIATED USE
EP4071170A4 (en) PHARMACEUTICAL COMPOSITION, ITS PREPARATION METHOD AND ITS USE
EP3943488A4 (en) SUBSTITUTED HETEROCYCLIC AMIDE COMPOUND AND METHOD FOR PREPARATION AND PHARMACEUTICAL USE
EP3686212A4 (en) PENTACYCLIC TRITERPENIC COMPOUND AND PROCESS FOR THE PREPARATION OF THE SAME, PHARMACEUTICAL COMPOSITION AND ASSOCIATED USE
EP4001267A4 (en) CONDENSED CYCLE PYRIMIDINE AMINO COMPOUND AND METHOD FOR THE PREPARATION, PHARMACEUTICAL COMPOSITION AND USE THEREOF
EP3967682A4 (en) BISHETEROCYCLIC-CARBONYL SUBSTITUTE DIHYDROPYRAZOLE COMPOUND, METHOD FOR PREPARING IT AND PHARMACEUTICAL USE
EP3438105A4 (en) DIARYL-B-LACTAM COMPOUND AND PROCESS FOR PREPARATION AND PHARMACEUTICAL USE THEREOF
EP3858833A4 (en) AMINONORDECANE DERIVATIVE, METHOD FOR PREPARATION AND USE
EP3594216A4 (en) FIVE AMINOPYRIMIDINE HETEROCYCLIC COMPOUND, INTERMEDIATE, METHOD OF PREPARATION, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF
EP3363803A4 (en) UREA-BASED PEEPTOID BORIC ACID COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, PREPARATION METHOD AND USES THEREOF
EP2781512A4 (en) OXADIAZOLE COMPOUND AND PROCESS FOR PREPARING THE SAME, PHARMACEUTICAL COMPOSITION AND USE THEREOF

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20210427

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40052595

Country of ref document: HK

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: C07D0401140000

Ipc: C07D0401040000

A4 Supplementary search report drawn up and despatched

Effective date: 20220524

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 29/00 20060101ALI20220518BHEP

Ipc: A61P 25/00 20060101ALI20220518BHEP

Ipc: A61P 37/00 20060101ALI20220518BHEP

Ipc: A61P 35/00 20060101ALI20220518BHEP

Ipc: A61K 31/538 20060101ALI20220518BHEP

Ipc: A61K 31/497 20060101ALI20220518BHEP

Ipc: A61K 31/4545 20060101ALI20220518BHEP

Ipc: A61K 31/454 20060101ALI20220518BHEP

Ipc: A61K 31/45 20060101ALI20220518BHEP

Ipc: C07D 405/14 20060101ALI20220518BHEP

Ipc: C07D 409/14 20060101ALI20220518BHEP

Ipc: C07D 417/14 20060101ALI20220518BHEP

Ipc: C07D 419/14 20060101ALI20220518BHEP

Ipc: C07D 498/10 20060101ALI20220518BHEP

Ipc: C07D 487/10 20060101ALI20220518BHEP

Ipc: C07D 491/107 20060101ALI20220518BHEP

Ipc: C07D 413/14 20060101ALI20220518BHEP

Ipc: C07D 401/14 20060101ALI20220518BHEP

Ipc: C07D 401/04 20060101AFI20220518BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20240827